Affiliation:
1. Federal Research Center of Coal and Coal Chemistry of the Siberian Branch of the Russian Academy of Sciences
2. Institute of Chemical Biology and Fundamental Medicine of the Siberian Branch of the Russian Academy of Sciences
3. Kemerovo State University
4. Kuzbass Clinical Oncology Dispensary
5. Kemerovo State Medical University;
Kemerovo Clinical Diagnostic Сenter
Abstract
Aim. To investigate the associations of idiotypic IgA antibodies against benzo[a]pyrene, estradiol and progesterone (IgA1 -Bp, IgA1 -E2, and IgA1 - Pg) with the corresponding anti-idiotypic IgG antibodies to estradiol and progesterone (IgG2 -E2 and IgG2 -Pg) and with gene polymorphisms of CYP1A1, CYP1A2, CYP1B1, CYP17A1, CYP19A1, GSTM1, GSTT1, and GSTP1 in patients with stage 1 breast cancer. Materials and Methods. Idiotypic and anti-idiotypic antibodies in the serum of 240 healthy women and 505 patients with stage 1 breast cancer were measured by enzyme-linked immunosorbent assay. Prevalence of CYP1A1 (rs4646903), CYP1A2 (rs762551), CYP1B1 (rs1056836), CYP19A1 (rs2470152), GSTM1(del), GSTT1(del), and GSTP1 (rs1695) polymorphisms in 530 healthy women and 694 patients with stage 1 breast cancer were determined by real-time polymerase chain reaction.Results. Low personal IgA1 -Bp/IgA1 -Pg < 1 and IgA1 -E2/IgA1 -Pg < 1 ratios in combination with low IgG2 -E2 ≤ 4 and high IgG2 -Pg > 2 levels were found in 20.6% of healthy women and in 4.5% of breast cancer patients (p < 0.0001; OR = 0.2). Low IgA1 -Bp/IgA1 -Pg and high IgA1 -E2/IgA1 -Pg ratios in combination with low IgG2 -E2 and high IgG2 - Pg levels were revealed in 7.4% of healthy women and 2.8% of breast cancer patients (p = 0.009; OR = 0.4). These two variants were integrated and marked as protective immunological phenotype. High IgA1 - Bp/IgA1 -Pg and high IgA1 -E2/IgA1 -Pg ratios combined with high IgG2 -Pg and high or low IgG2 -E2 levels were found in 17.2% of healthy women and27.2% of breast cancer patients (p = 0.006; OR = 1.8) and in 6.4% of healthy women and in 18.3% of breast cancer patients (p < 0.0001; OR = 3.3), correspondingly. These two variants were integrated and marked as pro-carcinogenic immunological phenotype. These associations were found only with estrogen receptor-positive (ER+) breast cancer. GSTP1 (rs1695) gene polymorphism was associated exclusively with estrogen receptor-negative (ER-) breast cancer (p = 0.004; OR = 1.56). No interrelations be tween immunological phenotypes and studied polymorphisms of CYP and GST genes have been found.Conclusion. Pro-carcinogenic immunological phenotype and rs1695 gene polymorphism within the GSTP1 gene were independent predictors of ER+ and ER- breast cancer correspondingly.
Publisher
Kemerovo State Medical University
Reference31 articles.
1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30. https://doi.org/10.3322/caac.21590
2. Kaprin AD, Starinsky VV, Shakhzadova AO, editors. Zlokachestvennyye novoobrazovaniya v Rossii v 2020 godu (zabolevayemost’ i smertnost’). Moscow : MNIOI imeni P.A. Gertsena - filial FGBU «NMITs radiologii» Minzdrava Rossii; 2021. (in Russ). https://oncology-association.ru/wpcontent/uploads/2021/11/zis-2020-elektronnaya-versiya.pdf
3. Imyanitov EN. The role of molecular genetic diagnosis in clinical oncology. Practical oncology. 2019;20(4):261-273. (in Russ). https://doi.org/10.31917/2004261
4. Sneha S, Baker SC, Green A, Storr S, Aiyappa R, Martin S, Pors K. Intratumoural Cytochrome P450 Expression in Breast Cancer: Impact on Standard of Care Treatment and New Efforts to Develop Tumour-Selective Therapies. Biomedicines. 2021;9(3):290. https://doi.org/10.3390/biomedicines9030290
5. FarmohammadiA, Arab-Yarmohammadi V, Ramzanpour R. Association analysis of rs1695 and rs113827 2 variations in GSTP1 gene and breast cancer susceptibility. Asian Pac J Cancer Prev. 2020;21(4):1167-1172. https://doi.org/10.31557/APJCP.2020.21.4.1167